Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 4/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328603 | 0.88 | ALDH1A1 (0.39) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL15328312 | 0.84 | P2RY2 (0.34) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL15328213 | 0.83 | CSNK2A2 (0.37) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL15328215 | 0.83 | CSNK2A2 (0.37) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL17074554 | 0.82 | P2RY2 (0.33) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL17074557 | 0.82 | P2RY2 (0.33) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL15341063 | 0.81 | STK17B (0.51) | P2RY2 | |
| SCHEMBL15344221 | 0.81 | CSNK2A2 (0.34) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL12470029 | 0.79 | CHEK1 (0.36) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL15328614 | 0.78 | CSNK2A2 (0.34) | P2RY2CSNK2A2CSNK2BCSNK2A1CSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169295-B2 | Macrocycles and macrocycle stabilized peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2627662-B1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | PTMS, VIP, MTPN | P2RY2 4398/4885CSNK2A2 2005/4885CSNK2B 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.